Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM): efficacy results after additional follow-up of the phase 2, randomized ELOQUENT-3 study

被引：0

作者：

Raab, M. S. ^{[1
]}

Dimopoulos, M. A. ^{[2
]}

Dytfeld, D. ^{[3
]}

Grosicki, S. ^{[4
]}

Moreau, P. ^{[5
]}

Takezako, N. ^{[6
]}

Hori, M. ^{[7
]}

Leleu, X. ^{[8
]}

LeBlanc, R. ^{[9
]}

Suzuki, K. ^{[10
]}

Richardson, P. G. ^{[11
]}

McKiver, Popa M. ^{[12
]}

Jou, Y. -M. ^{[12
]}

Shelat, S. G. ^{[12
]}

Robbins, M. ^{[13
]}

Rafferty, B. ^{[12
]}

San-Miguel, J. ^{[14
]}

机构：

[1] Heidelberg Univ Hosp, Dept Med 5, Heidelberg, Germany

[2] Natl & Kapodistrian Univ Athens, Athens, Greece

[3] Poznan Univ Med Sci, Poznan, Poland

[4] Silesian Med Univ, Katowice, Poland

[5] Univ Hosp, Nantes, France

[6] Natl Hosp Org Disaster Med Ctr, Tokyo, Japan

[7] Ibaraki Cent Hosp, Kasama, Ibaraki, Japan

[8] Ctr Hosp Univ Poitiers La Miletrie, Poitiers, France

[9] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada

[10] Japanese Red Cross Med Ctr, Tokyo, Japan

[11] Dana Farber Canc Inst, Boston, MA 02115 USA

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Bristol Myers Squibb, Cambridge, MA USA

[14] Clin Univ Navarra, Ctr Invest Med Aplicada, Idisna, Ciberonc, Pamplona, Spain

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P712

引用

页码：192 / 193

页数：2